Chongqing Zhifei Biological Products Co., Ltd.
Shenzhen Stock ExchangeTotal Valuation
Chongqing Zhifei Biological Products Co., Ltd. carries a market capitalization of 29.25B, placing it among publicly traded companies globally. Its enterprise value stands at 45.67B, reflecting the total theoretical takeover cost after accounting for cash holdings and debt obligations.
| Market Cap | 29.25B |
| Enterprise Value | 45.67B |
Share Statistics
Chongqing Zhifei Biological Products Co., Ltd. currently has 2.39B shares outstanding.
| Shares Outstanding | 2.39B |
| Owned by Insiders (%) | N/A |
| Owned by Institutions (%) | N/A |
Valuation Ratios
The price-to-sales ratio is 4.09, and the price-to-book ratio stands at 2.50.
| PE Ratio | N/A |
| PS Ratio | 4.09 |
| PB Ratio | 2.50 |
| P/TBV Ratio | 2.74 |
| P/FCF Ratio | 96.98 |
| P/OCF Ratio | N/A |
Enterprise Valuation
| EV / Sales | 5.22 |
| EV / EBITDA | N/A |
| EV / EBIT | N/A |
| EV / FCF | 78.38 |
Financial Position
Chongqing Zhifei Biological Products Co., Ltd. maintains a current ratio of 3.14, meaning it holds 3.1x the short-term assets needed to cover near-term liabilities. The debt-to-equity ratio is 71.94, indicating elevated leverage, while an interest coverage ratio of -11.81 demonstrates limited ability to service its debt obligations.
| Current Ratio | 3.14 |
| Quick Ratio | 0.33 |
| Debt / Equity | 71.94 |
| Debt / EBITDA | -3.78 |
| Interest Coverage | -11.81 |
Financial Efficiency
| Return on Equity (ROE) | -67.71 |
| Return on Assets (ROA) | -38.19 |
| Return on Invested Capital (ROIC) | N/A |
| Return on Capital Employed (ROCE) | N/A |
| Revenue Per Employee | N/A |
| Employee Count | N/A |
| Inventory Turnover | 0.64 |
Taxes
| Income Tax | -2.77B |
| Effective Tax Rate | N/A |
Stock Price Statistics
Chongqing Zhifei Biological Products Co., Ltd.'s stock has declined approximately -37.13992% over the past 52 weeks. The 50-day moving average sits at 13.64, while the 200-day moving average is 17.27.
| Beta (5Y) | N/A |
| 52-Week Price Change | -37.13992% |
| 50-Day Moving Average | 13.64 |
| 200-Day Moving Average | 17.27 |
| Average Volume (20 Days) | N/A |
Income Statement
Over the trailing twelve months, Chongqing Zhifei Biological Products Co., Ltd. generated 8.76B in revenue and converted that into -14.79B in net income, yielding earnings per share of -6.19. EBITDA reached -2.99B, while operating income came in at -2.99B.
| Revenue | 8.76B |
| Gross Profit | 576.35M |
| Operating Income | -2.99B |
| Pretax Income | -17.58B |
| Net Income | -14.79B |
| EBITDA | -2.99B |
| EBIT | -2.99B |
| Earnings Per Share (EPS) | -6.19 |
Balance Sheet
Chongqing Zhifei Biological Products Co., Ltd. holds 1.71B in cash and equivalents against 11.30B in total debt, resulting in a net debt position of 6.71B. Total book value stands at 14.35B, with working capital of 11.19B providing operational flexibility.
| Cash & Cash Equivalents | 1.71B |
| Total Debt | 11.30B |
| Net Debt | 6.71B |
| Equity (Book Value) | 14.35B |
| Book Value Per Share | 5.99 |
| Working Capital | 11.19B |
Cash Flow
After subtracting -369.32M in capital expenditures, free cash flow totaled -369.32M - equivalent to -0.15 per share.
| Operating Cash Flow | N/A |
| Capital Expenditures | -369.32M |
| Free Cash Flow | -369.32M |
| FCF Per Share | -0.15 |
Margins
Chongqing Zhifei Biological Products Co., Ltd. operates with a gross margin of 6.58, reflecting its pricing power and cost economics. The operating margin of -34.15 and net profit margin of -168.90 provide insight into operational efficiency.
| Gross Margin | 6.58 |
| Operating Margin | -34.15 |
| Pretax Margin | -200.82 |
| Profit Margin | -168.90 |
| EBITDA Margin | -34.15 |
Dividends & Yields
The company's payout ratio of -1.86 indicates the proportion of earnings distributed to shareholders.
| Dividend Per Share | 0.12 |
| Dividend Yield | N/A |
| Payout Ratio | -1.86 |
| Shareholder Yield | 13.14 |
| FCF Yield | 1.03 |
Stock Splits
Chongqing Zhifei Biological Products Co., Ltd.'s most recent stock split took place on June 16, 2023 with a 50:77 split ratio.
| Last Split Date | 6/16/2023 |
| Split Ratio | 50:77 |
Scores
Chongqing Zhifei Biological Products Co., Ltd. posts an Altman Z-Score of 2.70, near the 3.0 threshold that indicates strong financial health and minimal bankruptcy risk.
| Altman Z-Score | 2.70 |